75
Participants
Start Date
December 31, 2019
Primary Completion Date
April 29, 2024
Study Completion Date
April 29, 2024
Oral Cabotegravir (CAB)
30 mg tablets administered orally
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
NRTIs were not provided by the study. Participants obtained NRTIs outside of the study through routine care.
Long-Acting Injectable Cabotegravir (CAB LA)
600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
VRC07-523LS
40 mg/kg administered as an intravenous (IV) infusion
Standard of Care (SOC) ART
SOC ART was not provided by the study. Participants obtained SOC ART outside of the study through routine care.
Weill Cornell Chelsea CRS, New York
Weill Cornell Uptown CRS, New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester
Penn Therapeutics, CRS, Philadelphia
Johns Hopkins University CRS, Baltimore
Chapel Hill CRS, Chapel Hill
Alabama CRS, Birmingham
Ohio State University CRS, Columbus
Cincinnati Clinical Research Site, Cincinnati
Northwestern University CRS, Chicago
University of Colorado Hospital CRS, Aurora
UCSD Antiviral Research Center CRS, San Diego
Ucsf Hiv/Aids Crs, San Francisco
Washington University Therapeutics (WT) CRS, St Louis
New Jersey Medical School Clinical Research Center CRS, Newark
Columbia P&S CRS, New York
University of Washington AIDS CRS, Seattle
Puerto Rico AIDS Clinical Trials Unit CRS, San Juan
Collaborators (1)
ViiV Healthcare
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH